Much of his study explores Internal medicine relationship to Cohort study. Chong-Jen Yu conducts interdisciplinary study in the fields of Cancer and Pathology through his research. His Pathology study frequently intersects with other fields, such as Lung cancer. In his study, Chong-Jen Yu carries out multidisciplinary Lung cancer and Performance status research. In his research, Chong-Jen Yu performs multidisciplinary study on Performance status and Cancer. Chong-Jen Yu performs integrative study on Gefitinib and T790M in his works. With his scientific publications, his incorporates both T790M and Erlotinib. Chong-Jen Yu performs integrative Erlotinib and Afatinib research in his work. In his papers, Chong-Jen Yu integrates diverse fields, such as Afatinib and Gefitinib.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean;Cameron Brennan;Jin-Yuan Shih;Gregory Riely.
Proceedings of the National Academy of Sciences of the United States of America (2007)
MicroRNA Signature Predicts Survival and Relapse in Lung Cancer
Sung Liang Yu;Hsuan Yu Chen;Hsuan Yu Chen;Gee Chen Chang;Chih Yi Chen.
Cancer Cell (2008)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria;Daniel S W Tan;Rita Chiari;Yi-Long Wu.
The Lancet (2017)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
James C.H. Yang;Lecia V. Sequist;Sarayut Lucien Geater;Chun Ming Tsai.
Lancet Oncology (2015)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Yi-Long Wu;Masahiro Tsuboi;Jie He;Thomas John.
The New England Journal of Medicine (2020)
Value of sonography in determining the nature of pleural effusion: analysis of 320 cases.
Pan-Chyr Yang;Kwen-Tay Luh;Dun-Bing Chang;Huey-Dong Wu.
American Journal of Roentgenology (1992)
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony S.K. Mok;Yi-Long Wu;Jin Soo Lee;Chong-Jen Yu.
Clinical Cancer Research (2015)
Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer
Jenn-Yu Wu;Chong-Jen Yu;Yeun-Chung Chang;Chih-Hsin Yang.
Clinical Cancer Research (2011)
Mycobacterium abscessus Complex Infections in Humans.
Meng-Rui Lee;Wang-Huei Sheng;Chien-Ching Hung;Chong-Jen Yu.
Emerging Infectious Diseases (2015)
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
Yi Long Wu;Jin Soo Lee;Sumitra Thongprasert;Chong Jen Yu.
Lancet Oncology (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: